Eisen Alon, Fisman Enrique Z, Rubenfire Melvyn, Freimark Dov, McKechnie Ronald, Tenenbaum Alexander, Motro Michael, Adler Yehuda
Cardiac Rehabilitation Institute and Heart Failure Unit, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Atherosclerosis. 2004 Feb;172(2):201-10. doi: 10.1016/S0021-9150(03)00238-7.
The phenomenon of "ischemic preconditioning" has been recognized for almost two decades. In experimental animals and humans, a brief period of ischemia has been shown to protect the heart from more prolonged episodes of ischemia, and reduce the degree of impaired ventricular function or subsequent damage. Ischemic preconditioning is classified into two distinct components: the classic early preconditioning and the delayed or late preconditioning, each with its own biologic mechanism of adaptation. A comprehensive understanding of these mechanisms and application to clinical scenarios has the promise of providing unique opportunities, particularly regarding the development of preconditioning mimetic agents. Administration of these mimetic drugs or procedures could potentially advance the use of preconditioning as a therapeutic tool and/or preventive factor for cardiovascular disease.
“缺血预处理”现象已被认识近二十年。在实验动物和人类中,短暂的缺血已被证明可保护心脏免受更长时间的缺血发作影响,并降低心室功能受损程度或后续损伤程度。缺血预处理可分为两个不同的成分:经典的早期预处理和延迟或晚期预处理,每种都有其自身的生物学适应机制。全面了解这些机制并将其应用于临床情况有望提供独特的机会,特别是在预处理模拟剂的开发方面。给予这些模拟药物或实施这些模拟程序可能会推动将预处理作为心血管疾病的治疗工具和/或预防因素的应用。